Logo image
Back
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Journal article   Open access   Peer reviewed

Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis

Martin Bergman, Namita Tundia, Min Yang, Eli Orvis, Jerry Clewell and Arielle Bensimon
Advances in therapy, v 38(12), pp 5649-5661
Dec 2021
DOI: https://doi.org/10.1007/s12325-021-01930-4
PMID: 34636000
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1007/s12325-021-01930-4View
Published, Version of Record (VoR)CC BY-NC V4.0,  Open

Abstract

Antirheumatic Agents - economics Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - economics Clinical Trials, Phase III as Topic Drug Therapy, Combination Heterocyclic Compounds, 3-Ring - economics Heterocyclic Compounds, 3-Ring - therapeutic use Humans Methotrexate - economics Methotrexate - therapeutic use Piperidines - economics Piperidines - therapeutic use Pyrimidines - economics Pyrimidines - therapeutic use Pyrroles - therapeutic use Quality of Life Randomized Controlled Trials as Topic Treatment Outcome
To compare the economic benefit of upadacitinib combination therapy versus tofacitinib combination therapy and upadacitinib monotherapy versus methotrexate monotherapy from improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA). Data were analyzed from two trials of upadacitinib (SELECT-NEXT and SELECT-MONOTHERAPY) and one trial of tofacitinib (ORAL-Standard) that collected HRQOL measurements using the Short Form 36 (SF-36) Health Survey in patients with RA. Direct medical costs per patient per month (PPPM) for patients receiving upadacitinib 15 mg once daily and methotrexate were derived from observed SF-36 Physical (PCS) and Mental Component Summary (MCS) scores in the SELECT trials using a regression algorithm. Direct medical costs PPPM for patients receiving tofacitinib 5 mg twice daily were obtained from a published analysis of SF-36 PCS and MCS scores observed in the ORAL-Standard trial. Short-term (12-14 weeks) and long-term (48 weeks) estimates of direct medical costs PPPM were compared between upadacitinib and tofacitinib and between upadacitinib and methotrexate. Over 12 weeks, direct medical costs PPPM were $252 lower (95% CI $72, $446) for upadacitinib-treated patients versus tofacitinib-treated patients. Medical costs PPPM at weeks 24 and 48 and cumulative costs over the entire 48-week period (difference $1759; 95% CI $1162, $2449) were significantly lower for upadacitinib than for tofacitinib. Over 14 weeks, direct medical costs PPPM were $399 lower (95% CI $158, $620) for patients treated with upadacitinib monotherapy compared with those treated with methotrexate alone. Direct medical costs at week 48 and cumulative costs over the entire 48-week period (difference $2044; 95% CI $1221, $2846) were significantly lower for upadacitinib monotherapy compared with methotrexate alone. In the short and long term, upadacitinib combination therapy versus tofacitinib combination therapy and upadacitinib monotherapy versus methotrexate monotherapy were associated with significantly lower direct medical costs for patients with RA. ClinicalTrials.gov identifier, NCT02675426, NCT02706951, and NCT00853385.

Metrics

11 Record Views
6 citations in Web of Science
6 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Medicine, Research & Experimental
Pharmacology & Pharmacy
Logo image